H1N1 - Pipeline Review - 2019
Firstview Insight's H1N1 - Pipeline Review-2019 provides an overview of the pipeline landscape of H1N1 It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Influenza A virus subtype H1N1 is the subtype of influenza A virus that was the most common cause of human influenza (flu) in 2009, and is associated with the 1918 outbreak known as the Spanish flu. It is an orthomyxovirus that contains the glycoproteins haemagglutinin and neuraminidase. For this reason, they are described as H1N1, H1N2 etc. depending on the type of H or N antigens they express with metabolic synergy. Haemagglutinin causes red blood cells to clump together and binds the virus to the infected cell. Neuraminidase is a type of glycoside hydrolase enzyme which helps to move the virus particles through the infected cell and assist in budding from the host cells.
Some strains of H1N1 are endemic in humans and cause a small fraction of all influenza-like illness and a small fraction of all seasonal influenza. H1N1 strains caused a small percentage of all human flu infections in 2004–2005. Other strains of H1N1 are endemic in pigs (swine influenza) and in birds (avian influenza).
In June 2009, the World Health Organization (WHO) declared the new strain of swine-origin H1N1 as a pandemic. This strain is often called swine flu by the public media. This novel virus spread worldwide and had caused about 17,000 deaths by the start of 2010. On August 10, 2010, the World Health Organization declared the H1N1 influenza pandemic over, saying worldwide flu activity had returned to typical seasonal patterns.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
Influenza A virus subtype H1N1 is the subtype of influenza A virus that was the most common cause of human influenza (flu) in 2009, and is associated with the 1918 outbreak known as the Spanish flu. It is an orthomyxovirus that contains the glycoproteins haemagglutinin and neuraminidase. For this reason, they are described as H1N1, H1N2 etc. depending on the type of H or N antigens they express with metabolic synergy. Haemagglutinin causes red blood cells to clump together and binds the virus to the infected cell. Neuraminidase is a type of glycoside hydrolase enzyme which helps to move the virus particles through the infected cell and assist in budding from the host cells.
Some strains of H1N1 are endemic in humans and cause a small fraction of all influenza-like illness and a small fraction of all seasonal influenza. H1N1 strains caused a small percentage of all human flu infections in 2004–2005. Other strains of H1N1 are endemic in pigs (swine influenza) and in birds (avian influenza).
In June 2009, the World Health Organization (WHO) declared the new strain of swine-origin H1N1 as a pandemic. This strain is often called swine flu by the public media. This novel virus spread worldwide and had caused about 17,000 deaths by the start of 2010. On August 10, 2010, the World Health Organization declared the H1N1 influenza pandemic over, saying worldwide flu activity had returned to typical seasonal patterns.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
- The report provides a competitive landscape
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year
- To identifying prominent players in the treatment landscape
- To determine the drivers; barriers and unmet need in the treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
1. DISEASE OVERVIEW
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2090
3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR H1N1
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1 Drug 1
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Drug 2
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1 Drug 1
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Drug 2
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Drug 1
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Drug 2
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF H1N1
13. CONSTRAINTS OF H1N1
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2090
3. LIST OF COMPANIES DEVELOPING PRODUCTS FOR H1N1
4. TREATMENT ALGORITHM
5. CURRENT UNMET NEEDS
6. MARKET TRENDS
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1 Drug 1
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Drug 2
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1 Drug 1
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Drug 2
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
11. EARLY STAGE AND PRECLINICAL PRODUCTS (PHASE II)
11.1 Drug 1
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. Drug 2
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
12. DRIVERS OF H1N1
13. CONSTRAINTS OF H1N1
14. THERAPEUTIC ASSESSMENT
14.1. Assessment by Route of Administration
14.2. Assessment by Phase & Route of Administration
14.3. Assessment by Molecule Type
14.4. Assessment by Phase & Molecule type
14.5. Assessment by Target
14.6. Assessment by Mechanism of Action
15. COLLABORATIONS AND ACQUISITIONS DETAILS
16. DORMANT PRODUCTS
17. DISCONTINUED PRODUCTS
18. MARKET TRENDS
19. MARKET OPPORTUNITY ASSESSMENT
20. UNMET NEEDS
21. SWOT ANALYSIS
22. APPENDIX
23. REPORT METHODOLOGY
24. CONSULTING SERVICES
25. DISCLAIMER
LIST OF TABLES
Table 1: Marketed H1N1 drugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for H1N1
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
Table 1: Marketed H1N1 drugs, 2019
Table 2: Sales of Marketed drugs
Table 3: Patent expiration details – marketed drugs
Table 4: Number of Products Under Development for H1N1
Table 5: Products under Development by Companies
Table 6: Late Stage Products
Table 7: Mid Stage Products
Table 8: Early Stage Products
Table 9: Pre-Clinical and Discovery Products
Table 10: Assessment by Route of Administration
Table 11: Assessment by Stage and Route of Administration
Table 12: Assessment by Molecule Type
Table 13: Assessment by Stage and Molecule Type
Table 14: Assessment by Target
Table 15: Assessment by Mechanism of Action
Table 16: Dormant Products
Table 17: Discontinued Products
LIST OF FIGURES
Figure 1: Marketed and PipelineH1N1 drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for H1N1
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
Figure 1: Marketed and PipelineH1N1 drugs, 2019
Figure 2: Sales of Marketed drugs
Figure 3: Patent expiration details – marketed drugs
Figure 4: Number of Products Under Development for H1N1
Figure 5: Products under Development by Companies
Figure 6: Late Stage Products
Figure 7: Mid Stage Products
Figure 8: Early Stage Products
Figure 9: Pre-Clinical and Discovery Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Molecule Type
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Assessment by Target
Figure 15: Assessment by Mechanism of Action
Figure 16: Dormant Products
Figure17: Discontinued Products
